1. Munc18b is a major mediator of insulin exocytosis in rat pancreatic β-cells
- Author
-
Lain, Patrick P.L., Ohno, Mitsuyo, Dolai, Subhankar, He, Yu, Qin, Tairan, Liang, Tao, Zhu, Dan, Kang, Youhou, Liu, Yunfeng, Kauppi, Maria, Xie, Li, Wan, Wilson C.Y., Bin, Na-Rhum, Sugita, Shuzo, Olkkonen, Vesa M., Takahashi, Noriko, Kasai, Haruo, and Gaisano, Herbert Y.
- Subjects
Pancreatic beta cells -- Physiological aspects -- Genetic aspects -- Research ,Insulin -- Physiological aspects -- Genetic aspects -- Research ,Endocytosis -- Physiological aspects -- Genetic aspects -- Research ,Glucose metabolism -- Physiological aspects -- Genetic aspects -- Research ,Health - Abstract
Secl/Munc18 proteins facilitate the formation of trans-SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complexes that mediate fusion of secretory granule (SG) with plasma membrane (PM). The capacity of pancreatic β-cells to exocytose insulin becomes compromised in diabetes. β-Cells express three Munc18 isoforms of which the role of Munc18b is unknown. We found that Munc18b depletion in rat islets disabled SNARE complex formation formed by syntaxin (Syn)-2 and Syn-3. Two-photon imaging analysis revealed in Munc18b-depleted β-cells a 40% reduction in primary exocytosis (SG-PM fusion) and abrogation of almost all sequential SG-SG fusion, together accounting for a 50% reduction in glucose-stimulated insulin secretion (GSIS). In contrast, gain-of-function expression of Munc18b wild-type and, more so, dominant-positive K314L/R315L mutant promoted the assembly of cognate SNARE complexes, which caused potentiation of biphasic GSIS. We found that this was attributed to a more than threefold enhancement of both primary exocytosis and sequential SG-SG fusion, including long-chain fusion (6-8 SGs) not normally (2-3 SG fusion) observed. Thus, Munc18b-mediated exocytosis may be deployed to increase secretory efficiency of SGs in deeper cytosolic layers of β-cells as well as additional primary exocytosis, which may open new avenues of therapy development for diabetes., Glucose stimulation of islet β-cells triggers an initial robust first-phase glucose-stimulated insulin secretion (GSIS), followed by a diminished but sustained second-phase GSIS. In type 2 diabetes, islet insulin secretory capacity [...]
- Published
- 2013
- Full Text
- View/download PDF